Volume 6.16 | May 8

Prostate Cell News 6.16 May 8, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
 
TOP STORY
Tracking and Functional Characterization of Epithelial-Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis
Researchers report the first isolation and characterization of mesenchymal and epithelial-mesenchymal transition (EMT)-like tumor cells, which harbor both epithelial and mesenchymal characteristics, in an autochthonous murine model of prostate cancer. These EMT-like and mesenchymal tumor cells displayed enhanced stemness and invasive character compared to epithelial tumor cells. [Cancer Res] Abstract
Learn More: Standardized Tools for Cancer Research
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

KU675, a Concomitant Heat Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells
Researchers report a novel C-terminal 90-kDa heat shock protein (Hsp90) inhibitor, designated KU675, which exhibited potent anti-proliferative and cytotoxic activity along with client protein degradation without induction of the heat shock response in both androgen dependent and independent prostate cancer cell lines. [Mol Pharmacol] Abstract | Full Article

Galectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell Migration
The authors showed that polymerase I and transcript release factor expression (PTRF) in PC3 cells reduced focal adhesion kinase stabilization in focal adhesions and reduced cell motility without affecting phosphorylated caveolin-1 levels. [PLoS One] Full Article

An Atomic Force Microscope Study Revealed Two Mechanisms in the Effect of Anticancer Drugs on Rate-Dependent Young’s Modulus of Human Prostate Cancer Cells
The effects of eight different anticancer drugs on the mechanical properties of human prostate cancer cell were investigated using a recently developed control-based nanoindentation measurement protocol on atomic force microscope. [PLoS One] Full Article

MicroRNA-19a Regulates Proliferation and Apoptosis of Castration-Resistant Prostate Cancer Cells by Targeting BTG1
Researchers found that microRNA (miR)-19a expression was significantly increased in castration-resistant prostate cancer (CRPC) tissues compared with androgen-dependent prostate cancer tissues. They found that inhibiting the overexpression of miR-19a in CRPC cells suppressed proliferation and increased apoptosis. [FEBS Lett] Abstract

Overexpression of miR-145-5p Inhibits Proliferation of Prostate Cancer Cells and Reduces SOX2 Expression
Investigators performed functional analysis of miR-145-5p in prostate cancer (PCa) cells and identified targets of miR-145-5p for understanding its role in PCa pathogenesis. PC3, DU145, LNCaP PCa, and PNT1a nontumorigenic prostate cell lines were utilized for functional analysis of miR-145-5p. [Cancer Invest] Abstract

Castration-Resistant Lgr5+ Cells Are Long-Lived Stem Cells Required for Prostatic Regeneration
Investigators demonstrated that leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) is expressed in a rare population of prostate epithelial progenitor cells, and a castration-resistant Lgr5+ population exists in regressed prostate tissue. [Stem Cell Rep] Full Article | Graphical Abstract

The Androgen Receptor Plays a Suppressive Role in Epithelial-Mesenchymal Transition of Human Prostate Cancer Stem Progenitor Cells
Scientists investigated the roles of androgen receptor in epithelial-mesenchymal transition (EMT) in human prostate cancer stem progenitor (S/P) cells isolated from LNCaP cell line. The data showed that S/P cells from LNCaP had high EMT markers expression, more tumorigenesis and strong migration ability. [BMC Biochemistry] Abstract | Full Article

CLINICAL RESEARCH

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer
Scientists evaluated whether statin use prolonged time to progression during androgen deprivation therapy for hormone-sensitive prostate cancer. [JAM-J AM Med Assoc] Full Article | Press Release

Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control Arm Cross-Over to Salvage Immunotherapy
Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic/minimally symptomatic metastatic castrate-resistant prostate cancer. Investigators explored APC8015F’s effects on control-arm overall survival and treatment effects of sipuleucel-T vs. control adjusted for APC8015F treatment. [Cancer Immunol Res] Abstract | Full Article

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
 
REVIEWS
Regulation of Tumor Cell Plasticity by the Androgen Receptor in Prostate Cancer
The authors review the cellular plasticity, induced by androgen deprivation. They also address the emergence of cancer stem-like cells, epithelial-to-mesenchymal or myeloid plasticity, and neuroendocrine transdifferentiation and evidence supporting how each is regulated by the AR. [Endocr Relat Cancer] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
New Anti-Cancer Stem Cell Compound in Development
Scientists have developed a novel anti-cancer stem cell agent capable of targeting aggressive tumor forming cells common to breast, pancreas, colon and prostate cancers. The new OH14 compound has been licensed by Tiziana Life Sciences, a British-based pharmaceutical company. [Cardiff University] Press Release

$2 Million Grant to Fund Initial Clinical Trials in Prostate Cancer
An imaging agent discovered by a Washington State University researcher that homes in on prostate cancer will be developed for human clinical trials thanks to a two-year $2 million federal Small Business Innovation Research grant. [Washington State University] Press Release

UB Spinoff Gets $2 Million for Research on Cancer Therapy
For-Robin, a University at Buffalo (UB) spinoff company, has received a $2 million grant from the National Cancer Institute to study and develop a promising potential treatment for breast and other types of cancer, UB and U.S. Congressman Brian Higgins have announced. [University of Buffalo] Press Release

From our sponsor: Working with blood? Request your free wallchart on human blood cell frequencies.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Cell Death
September 15-19, 2015
Cold Spring Harbor, United States

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Positions – Molecular Cancer Biology (University of Pennsylvania)

NEW Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)

NEW Postdoctoral Research Fellow/Instructor – Prostate/Breast Cancer (Baylor College of Medicine)

Scientific Officer – Prostate Oncobiology Group (Cancer Research UK Manchester Institute)

Postdoctoral Fellow – Genitourinary Cancers (Geisinger Health System)

Cancer Biologist (Wake Forest Baptist Medical Center)

Postdoctoral Research Fellow – Prostate Cancer and Breast Cancer (Baylor College of Medicine)

Postdoctoral Fellow – Development, Progression and Chemotherapy Resistance of Cancers (University of Maryland School of Medicine)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us